GGrantIndex
← Leaderboards

Kathleen E. Rodgers

Maret Pharmaceuticals

Google Scholar ↗PubMed ↗ORCID ↗
$30,831,052
Attributed
$56,856,823
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $10.1M · FY2005–25
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$56,856,823 · 12

By mechanism

R01$38,574,413 · 2
U01$6,492,029 · 1
R44$4,241,420 · 2
RC1$2,955,600 · 2
R25$2,592,177 · 3
P01$1,901,184 · 1

Top collaborators

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposEvaluationSiteLaboratoriesLinkDoseBrainAngiotensinsPreventS DiseaseMeetingsToxicologyChronicProgramsS Disease ModelAffectBloodClinical ResearchDesignUnited States National Institutes Of HealthCommunitiesGrantDiagnosisPharmaceutical Preparations

Grant awards (40)

Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$6,580,973
R01 · FY2025 · AG
Project 3: Peripheral Immune Activation on the Road to Development of Alzheimer's Disease: Therapeutic Targets and Windows$347,094
P01 · FY2025 · AG · contact PI
Diversity in Research Education in Aging Medicine and Science$288,268
R25 · FY2025 · AG · contact PI
Neuroscience Diversity to Elevate Education and Research Development$269,196
R25 · FY2025 · NS · contact PI
Project 3: Peripheral Immune Activation on the Road to Development of Alzheimer's Disease: Therapeutic Targets and Windows$406,127
P01 · FY2024 · AG · contact PI
Diversity in Research Education in Aging Medicine and Science$288,268
R25 · FY2024 · AG · contact PI
Neuroscience Diversity to Elevate Education and Research Development$269,196
R25 · FY2024 · NS · contact PI
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,279,977
R01 · FY2023 · AG
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.$1,528,567
U01 · FY2023 · AG · contact PI
Project 3: Peripheral Immune Activation on the Road to Development of Alzheimer's Disease: Therapeutic Targets and Windows$406,127
P01 · FY2023 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$236,515
R25 · FY2023 · NS · contact PI
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,552,351
R01 · FY2022 · AG
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.$1,515,611
U01 · FY2022 · AG · contact PI
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.$383,750
U01 · FY2022 · AG · contact PI
Project 3: Peripheral Immune Activation on the Road to Development of Alzheimer's Disease: Therapeutic Targets and Windows$370,515
P01 · FY2022 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$236,515
R25 · FY2022 · NS · contact PI
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$7,370,815
R01 · FY2021 · AG
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.$1,531,012
U01 · FY2021 · AG · contact PI
Project 3: Peripheral Immune Activation on the Road to Development of Alzheimer's Disease: Therapeutic Targets and Windows$371,321
P01 · FY2021 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$238,809
R25 · FY2021 · NS · contact PI
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.$1,533,089
U01 · FY2020 · AG · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$264,089
R25 · FY2020 · NS · contact PI
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$246,522
R25 · FY2020 · NS · contact PI
Allopregnanolone as Regenerative Therapeutic for Alzheimer's: Phase 2 Clinical Trial$8,410,912
R01 · FY2019 · AG
Undergraduate Readying for Burgeoning Research for American Indian Neuroscientists$254,799
R25 · FY2019 · NS · contact PI
Angiotensin(1-7): A Target in Diabetic Cardiac Ischemia$340,178
R01 · FY2011 · HL · contact PI
NorLeu3-A(1-7): Enhanced Recovery of Radiation Burns$674,313
RC1 · FY2010 · AI · contact PI
A(1-7)-Mediated Mitigation of Radiation Induced Thrombocytopenia$431,578
RC1 · FY2010 · AI · contact PI
Angiotensin(1-7): A Target in Diabetic Cardiac Ischemia$340,503
R01 · FY2010 · HL · contact PI
Angiotensin Analogs to Treat Wound Healing$207,309
R44 · FY2010 · DK · contact PI
Angiotensin Analogs to Treat Wound Healing$860,819
R44 · FY2009 · DK · contact PI
Angiotensin(1-7): A Target in Diabetic Cardiac Ischemia$341,477
R01 · FY2009 · HL · contact PI
NorLeu3-A(1-7): Enhanced Recovery of Radiation Burns$942,319
RC1 · FY2008 · AI · contact PI
A(1-7)-Mediated Mitigation of Radiation Induced Thrombocytopenia$907,390
RC1 · FY2008 · AI · contact PI
Angiotensin Analogs to Treat Wound Healing$859,214
R44 · FY2008 · DK · contact PI
Angiotensin(1-7): A Target in Diabetic Cardiac Ischemia$357,227
R01 · FY2008 · HL · contact PI
Angiotensin Analogs to Treat Wound Healing$924,089
R44 · FY2007 · DK · contact PI
Angiotensin Analogs to Treat Wound Healing$429,652
R44 · FY2005 · AR
Angiotensin Analogs to Treat Wound Healing$960,337
R44 · FY2004 · AR
ANGIOTENSIN ANALOGS TO TREAT WOUND HEALING$100,000
R43 · FY2001 · AR